Literature DB >> 7905414

Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells.

P J Cohen1, P A Cohen, S A Rosenberg, S I Katz, J J Mulé.   

Abstract

We examined the ability of epidermal Langerhans cells and splenic dendritic cells to present tumor-associated antigens (Ag) to immune T cells. Methylcholanthrene (MCA)-induced subcutaneous fibrosarcomas derived from C57BL/6 mice were used as tumor models. Our data demonstrate that both murine Langerhans cells and splenic dendritic cells have the capacity to present tumor-associated Ag to primed T cells. We found that variously treated tumor preparations (irradiated viable tumor cells, irradiated frozen-stored tumor cells, mitomycin C-treated viable tumor cells, and snap freeze-thawed tumor cell lysates) can be utilized for tumor Ag-pulsing. Primed CD4+ T cells demonstrated in vitro specificity towards their respective tumors and did not cross-react to other syngeneic MCA-induced or non-MCA-induced tumors. The T cell proliferative response critically depended on the presence of immune CD4+ T cells. We discuss the implications of these findings for the adoptive immunotherapy of cancer using immune CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7905414     DOI: 10.1002/eji.1830240206

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  14 in total

Review 1.  The development of dendritic cell vaccine-based immunotherapies for glioblastoma.

Authors:  David A Reardon; Duane A Mitchell
Journal:  Semin Immunopathol       Date:  2017-01-30       Impact factor: 9.623

2.  Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis.

Authors:  N Seo; Y Tokura; T Nishijima; H Hashizume; F Furukawa; M Takigawa
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

3.  Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses.

Authors:  T Ishida; S Chada; M Stipanov; S Nadaf; F I Ciernik; D I Gabrilovich; D P Carbone
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

4.  Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines.

Authors:  K Shimizu; R C Fields; M Giedlin; J J Mulé
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

5.  Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy.

Authors:  M A Morse; L J Zhou; T F Tedder; H K Lyerly; C Smith
Journal:  Ann Surg       Date:  1997-07       Impact factor: 12.969

6.  Role of granulocyte macrophage colony-stimulating factor in host defense against pulmonary Cryptococcus neoformans infection during murine allergic bronchopulmonary mycosis.

Authors:  Gwo-Hsiao Chen; Michal A Olszewski; Roderick A McDonald; Jason C Wells; Robert Paine; Gary B Huffnagle; Galen B Toews
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

7.  Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo.

Authors:  R C Fields; K Shimizu; J J Mulé
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

8.  DC-SIGN reacts with TLR-4 and regulates inflammatory cytokine expression via NF-κB activation in renal tubular epithelial cells during acute renal injury.

Authors:  D Feng; Y Wang; Y Liu; L Wu; X Li; Y Chen; Y Chen; Y Chen; C Xu; K Yang; T Zhou
Journal:  Clin Exp Immunol       Date:  2017-10-05       Impact factor: 4.330

Review 9.  The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.

Authors:  Peter E Fecci; Duane A Mitchell; Gary E Archer; Michael A Morse; H Kim Lyerly; Darell D Bigner; John H Sampson
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

10.  Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines.

Authors:  P Brossart; M J Bevan
Journal:  Blood       Date:  1997-08-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.